Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 3/20 | 0.53 |
| ▸ | CDC25B | P30305 | 2/20 | 0.53 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.44 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.40 |
| ▸ | ATIC | P31939 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25314057 | 1.00 | CDC25A (0.53) | CDC25ACDC25BCYP24A1NR1H4GPBAR1 | |
| SCHEMBL25313067 | 0.94 | CYP24A1 (0.57) | CDC25ACDC25BCYP24A1NR1H4GPBAR1 | |
| SCHEMBL25313070 | 0.94 | CYP24A1 (0.57) | CDC25ACDC25BCYP24A1NR1H4GPBAR1 | |
| SCHEMBL10125344 | 0.90 | CDC25A (0.49) | CDC25ACDC25BCYP24A1NR1H4ST6GAL1 | |
| SCHEMBL14107816 | 0.90 | CDC25A (0.49) | CDC25ACDC25BCYP24A1NR1H4ST6GAL1 | |
| SCHEMBL9010672 | 0.90 | CDC25A (0.49) | CDC25ACDC25BCYP24A1NR1H4ST6GAL1 | |
| SCHEMBL13790493 | 0.90 | CDC25A (0.49) | CDC25ACDC25BCYP24A1NR1H4ST6GAL1 | |
| SCHEMBL10041409 | 0.90 | CDC25A (0.49) | CDC25ACDC25BCYP24A1NR1H4ST6GAL1 | |
| SCHEMBL9718383 | 0.90 | CDC25A (0.49) | CDC25ACDC25BCYP24A1NR1H4ST6GAL1 | |
| SCHEMBL10712009 | 0.90 | CDC25A (0.49) | CDC25ACDC25BCYP24A1NR1H4ST6GAL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195488-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | TEIJIN PHARMA LIMITED (JP) | 2025-06-19 | — | — | US | disclosed |
| EP-4491185-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | Teijin Pharma Limited (JP) | 2025-01-15 | — | — | EP | disclosed |
| US-20230348376-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | TEIJIN PHARMA LIMITED (JP) | 2023-11-02 | — | — | US | disclosed |
| WO-2023171736-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | 帝人ファーマ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| EP-4215519-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | Teijin Pharma Limited (JP) | 2023-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195488-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | VDR, CYP24A1, AQP4 | CDC25A 1518/4885CDC25B 1828/4885CYP24A1 2/4885 |
| US-20230348376-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | VDR, CYP2R1, CYP24A1 | CDC25A 2524/4885CDC25B 2864/4885CYP24A1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.